Maze Therapeutics’ Coloma proposes $1.09M share sale
The proposed sale is allocated between two trusts, with UBS Financial Services Inc. named as broker.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Maze Therapeutics, Inc. (MAZE) is named as issuer in a Rule 144 notice for a proposed sale of 34,501 common shares for Jason V. Coloma, an officer. The notice lists UBS Financial Services Inc. as broker, an aggregate market value of $1,093,681.70, and November 2, 2026 as the proposed sale date. Its remarks attribute 2,593 shares to The Coloma 2021 Irrevocable Trust and 31,908 shares to Coloma Family Trust.
Key Figures
Key Terms
Rule 144 regulatory
aggregate market value financial
attorney-in-fact technical
irrevocable trust technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What recent MAZE sales are listed for the two trusts?
AI-generated analysis. How Rhea-AI works. Not financial advice.